However, their specificity decreases if CTCs acquire a mesenchymal-like phenotype (including decreased surface expression of EpCAM) following the epithelial–mesenchymal transition and is low for CTCs derived from non-epithelial origin cancers (e.g., melanoma) [9,10,11]. Here, EPCAM is linked to cancer.